Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:PRTA

Prothena Q3 2024 Earnings Report

Prothena logo
$11.18 -0.01 (-0.09%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$11.18 0.00 (0.00%)
As of 05/6/2026 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Prothena EPS Results

Actual EPS
-$1.10
Consensus EPS
-$1.18
Beat/Miss
Beat by +$0.08
One Year Ago EPS
$0.38

Prothena Revenue Results

Actual Revenue
$0.97 million
Expected Revenue
$1.22 million
Beat/Miss
Missed by -$250.00 thousand
YoY Revenue Growth
-98.90%

Prothena Announcement Details

Quarter
Q3 2024
Date
11/12/2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Prothena's Q1 2026 earnings is estimated for Thursday, May 7, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q1 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

Prothena's Q3 2024 Press ReleasePress Release
(8-K)
Prothena's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Prothena Earnings Headlines

Prothena to Report First Quarter 2026 Financial Results on May 7
April 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260430688502/en/prothena-to-report-first-quarter-2026-financial-results-on-may-7/
Prothena announces Novo Nordisk obtains fast track designation from the US FDA for Coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy
April 27, 2026  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/prothena-announces-novo-nordisk-obtains-fast-track-designation-from-the-us-fda-for-coramitug-prx004-in-attr-amyloidosis-with-cardiomyopathy/ar-AA21Rnod
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
 |  Brownstone Research (Ad)
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
April 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260427325583/en/prothena-announces-novo-nordisk-obtains-fast-track-designation-from-the-u.s.-fda-for-coramitug-prx004-in-attr-amyloidosis-with-cardiomyopathy/
Prothena Announces Leadership Team Updates
April 10, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260410894357/en/prothena-announces-leadership-team-updates/
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026
March 21, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260321254343/en/prothena-partners-present-data-supporting-next-generation-treatments-for-parkinson%e2%80%99s-and-alzheimer%e2%80%99s-disease-at-adpd%e2%84%a2-2026/
See More Prothena Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prothena? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prothena and other key companies, straight to your email.

About Prothena

Prothena (NASDAQ:PRTA) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials. Additional pipeline candidates include therapies for amyloid light chain (AL) amyloidosis and other protein misfolding disorders. Prothena collaborates with global pharmaceutical partners to further develop and commercialize its product candidates, pooling resources and expertise to accelerate research timelines.

Founded in 2012 as a spin-out from Elan Corporation, Prothena is headquartered in South San Francisco, California, with research operations in both the United States and Ireland. The company maintains a global focus, engaging regulators and trial sites across North America, Europe and Asia to support its clinical development programs. Prothena’s commitment to addressing high-unmet-need diseases is reflected in its strategic partnerships and research investments.

Prothena is led by President and Chief Executive Officer Gene Kinney, whose experience spans decades in the pharmaceutical and biotechnology sectors. Under his leadership, the company has built a multidisciplinary team of scientists, clinicians and commercial experts. Prothena’s board and management team bring deep expertise in protein science, immunology and drug development to guide the company’s mission of bringing new treatment options to patients worldwide.

View Prothena Profile
Earnings Tools